Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential05 Jan 2011 • by Natalie Aster
London – “The overall market for five indications - breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL) - was at $153.4m in 2009. This is expected to grow at a CAGR of 11.3% for the next eight years and will reach $361.9m.”
The report “Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential” by GBI Research provides insights into oncology sales and price forecasts until 2017. The report also examines the Indian oncology treatment usage patterns. In addition, the report also includes insights into the oncology R&D pipeline. The report provides an in-depth analysis of the top five oncology therapeutic indications, which are breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL).
High Growth Rate and Increasing use of Biologics has made the Oncology Market Attractive
Published: December 2010
Price: USD 3,500
Report Sample Abstract:
High Support by Government and Increasing Incidence Rate among Large Population Base are not Big Enough Drivers for High Market Growth
The major drivers are large population base and increasing incidence rate, along with government support. However, the number of restraints is much higher than the drivers. Major restraints are pricing and patent issues. This has created a lot of issues in the past. Tarceva and Glivec are two famous cases which are still pending in court.
Along with these factors, reimbursement is also a major restraint. There are very few health policies which cover cancer diseases. Companies which provide such coverage either charge very high premiums or their conditions are very restrictive. Thus the Indian population is not able to fully utilize the benefits of newly developed drugs.
Strong Pipeline and the Entry of New Players Will Intensify the Competition
The global oncology market has a strong pipeline base that will support the growth of this market, thereby attracting many pharmaceutical and biotechnological companies. Major molecules are in Phase II and Phase III, so a high chance of intense competition can be predicted.
Major pharmaceutical companies such as Pfizer, Astrazeneca, Sanofi-Aventis, Merck, Roche and Novartis are active in their pipeline for oncology. The rapid entry of new players and the highly active pipeline will intensify competition.
More information can be found in the report “Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential” by GBI Research.
To order the report or ask for sample pages contact email@example.com